

Title (en)

THERAPEUTIC COMPOSITIONS OF SPECIFIED HERBAL FORMULATIONS AND USES THEREOF

Title (de)

THERAPEUTISCHE ZUSAMMENSETZUNGEN AUS BESTIMMTEN KRÄUTERFORMULIERUNGEN UND VERWENDUNGEN DAVON

Title (fr)

COMPOSITIONS THÉRAPEUTIQUES DE FORMULATIONS À BASE D'HERBES SPÉCIFIÉES ET LEURS UTILISATIONS

Publication

EP 3403663 A1 20181121 (EN)

Application

EP 17201472 A 20120515

Priority

- US 201161486724 P 20110516
- EP 12865478 A 20120515
- US 2012037974 W 20120515

Abstract (en)

Disclosed herein are herbal formulations developed for the management of acute and chronic inflammatory conditions and infectious diseases. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

IPC 8 full level

A61K 36/185 (2006.01); **A61K 36/22** (2006.01); **A61K 36/23** (2006.01); **A61K 36/27** (2006.01); **A61K 36/28** (2006.01); **A61K 36/29** (2006.01); **A61K 36/31** (2006.01); **A61K 36/35** (2006.01); **A61K 36/48** (2006.01); **A61K 36/66** (2006.01); **A61K 36/68** (2006.01); **A61K 36/71** (2006.01); **A61K 36/76** (2006.01); **A61K 36/77** (2006.01); **A61K 36/808** (2006.01); **A61K 36/899** (2006.01); **A61K 36/90** (2006.01)

CPC (source: EP US)

A61K 36/185 (2013.01 - EP US); **A61K 36/22** (2013.01 - EP US); **A61K 36/23** (2013.01 - EP US); **A61K 36/24** (2013.01 - EP US); **A61K 36/27** (2013.01 - EP US); **A61K 36/28** (2013.01 - EP US); **A61K 36/29** (2013.01 - EP US); **A61K 36/31** (2013.01 - EP US); **A61K 36/35** (2013.01 - EP US); **A61K 36/48** (2013.01 - EP US); **A61K 36/66** (2013.01 - EP US); **A61K 36/68** (2013.01 - EP US); **A61K 36/71** (2013.01 - EP US); **A61K 36/76** (2013.01 - EP US); **A61K 36/77** (2013.01 - EP US); **A61K 36/808** (2013.01 - EP US); **A61K 36/899** (2013.01 - EP US); **A61K 36/90** (2013.01 - EP US); **A61P 1/00** (2017.12 - EP); **A61P 9/14** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/08** (2017.12 - EP); **A61P 13/10** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (applicant)

- "Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
- LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
- MATTHEWS, HB; LUCIER, GW; FISHER, KD: "Medicinal herbs in the United States: research needs", ENVIRON HEALTH PERSPECT, vol. 107, no. 10, 1999, pages 773 - 8
- TINDLE, HA; DAVIS, RB; PHILLIPS, RS ET AL.: "Trends in use of complementary and alternative medicine by US adults: 1997-2002", ALTERN THER HEALTH MED, vol. 11, no. 1, 2005, pages 42 - 9
- NORMILE, D: "Asian medicine. The new face of traditional Chinese medicine", SCIENCE, vol. 299, no. 5604, 2003, pages 188 - 90
- IAU, L; LO BUE, AM; MILAZZO, I ET AL.: "Antibacterial activity of medicinal plant extracts against periodontopathic bacteria", PHYTOTHER RES, vol. 17, no. 6, 2003, pages 599 - 604
- GUO, R; PITTLER, MH; ERNST, E: "Complementary medicine for treating or preventing influenza or influenza-like illness", AM J MED, vol. 120, no. 11, 2007, pages 923, XP022318707, DOI: doi:10.1016/j.amjmed.2007.06.031
- Cwikla, C; Schmidt, K; Matthias, A ET AL.: "Investigations into the antibacterial activities of phytotherapeutics against Helicobacter pylori and Campylobacter jejuni", PHYTOTHER RES, 2009
- ATTARDO, C; SARTORI, F: "Pharmacologically active plant metabolites as survival strategy products", BOLL CHIM FARM, vol. 142, no. 2, 2003, pages 54 - 65
- WOLFF, HH; KIESER, M: "Hamamelis in children with skin disorders and skin injuries: results of an observational study", EUR J PEDIATR, vol. 166, no. 9, 2007, pages 943 - 8, XP019542530
- HORII, KA; SIMON, SD; LIU, DY ET AL.: "Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns", PEDIATRICS, vol. 120, no. 3, 2007, pages e527 - 34
- LEUNG, DY; BIEBER, T: "Atopic dermatitis", LANCET, vol. 361, no. 9352, 2003, pages 151 - 60, XP027155254, DOI: doi:10.1016/S0140-6736(03)12193-9
- ABRAMOVITS, W; PERLMUTTER, A: "Steroids versus other immune modulators in the management of allergic dermatoses", CURR OPIN ALLERGY CLIN IMMUNOL, vol. 6, no. 5, 2006, pages 345 - 54
- MCCLAIN, RW; YENTZER, BA; FELDMAN, SR: "Comparison of skin concentrations following topical versus oral corticosteroid treatment: reconsidering the treatment of common inflammatory dermatoses", J DRUGS DERMATOL, vol. 8, no. 12, 2009, pages 1076 - 9
- TAKEUCHI, O; HOSHINO, K; KAWAI, T ET AL.: "Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components", IMMUNITY, vol. 11, no. 4, 1999, pages 443 - 51, XP002927803, DOI: doi:10.1016/S1074-7613(00)80119-3
- NIEBUHR, M; LUTAT, C; SIGEL, S ET AL.: "Impaired TLR-2 expression and TLR-2-mediated cytokine secretion in macrophages from patients with atopic dermatitis", ALLERGY, 2009
- S. WIRTZ; M.F. NEURATH: "Mouse models of inflammatory bowel disease", ADV DRUG DELIV REV, vol. 59, 2007, pages 1073 - 1083, XP022312888, DOI: doi:10.1016/j.addr.2007.07.003
- L.F. POLI-DE-FIGUEIREDO; A.G. GARRIDO; N. NAKAGAWA; P. SANNOMIYA: "Experimental models of sepsis and their clinical relevance", SHOCK, vol. 30, no. 1, 2008, pages 53 - 59
- HATANO, Y; MAN, MQ; UCHIDA, Y ET AL.: "Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators", J ALLERGY CLIN IMMUNOL, vol. 125, no. 1, 2010, pages 160
- MAN, MQ; HATANO, Y; LEE, SH ET AL.: "Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges", J INVEST DERMATOL, vol. 128, no. 1, 2008, pages 79 - 86
- ORANJE, AP; GLAZENBURG, EJ; WOLKERSTORFER, A ET AL.: "Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score", BR J DERMATOL, vol. 157, no. 4, 2007, pages 645 - 8
- WOLKERSTORFER, A; DE WAARD VAN DER SPEK, FB; GLAZENBURG, EJ ET AL.: "Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies", ACTA DERM VENEREOL, vol. 79, no. 5, 1999, pages 356 - 9

- JENEROWICZ, D; CZARNECKA-OPERACZ, M; SILNY, W: "Peripheral blood eosinophilia in atopic dermatitis", ACTA DERMATOVENEROL ALP PANONICA ADRIAT, vol. 16, no. 2, 2007, pages 47 - 52
- ORANJE, AP; STALDER, JF; TAIEB, A ET AL.: "Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines", PEDIATR ALLERGY IMMUNOL, vol. 8, 1997, pages 28 - 4
- SPRIKKELMAN, AB; TUPKER, RA; BURGERHOF, H ET AL.: "Severity scoring of atopic dermatitis: a comparison of three scoring systems", ALLERGY, vol. 52, 1997, pages 944 - 9, XP055152759, DOI: doi:10.1111/j.1398-9995.1997.tb01255.x

Citation (search report)

No Search

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

US 2013149398 A1 20130613; US 9050359 B2 20150609; CN 103687606 A 20140326; CN 103687606 B 20180817; CN 108853403 A 20181123; EP 2709642 A2 20140326; EP 2709642 A4 20150826; EP 3403663 A1 20181121; US 2015265668 A1 20150924; US 2018161387 A1 20180614; US 2020368308 A1 20201126; US 2022184169 A1 20220616; US 9889174 B2 20180213; WO 2013106068 A2 20130718; WO 2013106068 A3 20140109

DOCDB simple family (application)

US 201213471913 A 20120515; CN 201280035451 A 20120515; CN 201810817659 A 20120515; EP 12865478 A 20120515; EP 17201472 A 20120515; US 2012037974 W 20120515; US 201514733771 A 20150608; US 201815889921 A 20180206; US 202016842528 A 20200407; US 202217684811 A 20220302